---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-005219"
form_type: "8-K/A"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:05:33.695948+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Raphael Pharma corrects CTO deal: $9k/month, 999k warrants at $0.01, royalty share

## Summary
- Service agreement with CTO Dr. Igal Louria Hayon corrected, monthly fee $9,000 through Dec 31, 2022.
- Issuance of 999,000 warrants at $0.01 per share, expiring July 5, 2024.
- Additional 350,000 warrants at $0.01 if company initiates cannabis clinical trial or new cannabis research.
- Royalty payments: 15% of net royalties from medical cannabis CBD oil for COVID-19 and for rheumatoid arthritis.
- Term through Dec 31, 2023; termination requires 120 days notice and fee equal to remaining monthly fees.

## SEC filing metadata
- accession: 0001213900-23-005219
- form_type: 8-K/A
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390023005219/0001213900-23-005219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390023005219/ea172085-8ka1_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-005219
- JSON: https://secwatch.observer/filing/0001213900-23-005219.json
- Plain text: https://secwatch.observer/filing/0001213900-23-005219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.